18
Chiang L.M., Darras B.T., Kang P.B. Juvenile myasthenia gravis // Muscle. Nerve.
–
2009.
–
Vol. 39, № 4. –
P. 423-431.
Chiu H.C., Chen W.H., Yah J.H. Double filtration plasmapheresis in the treatment of
inflammatory polyneyropathy // Ther. Apher.
–
1997.
–
Vol. 1, № 2. –
P. 183-186.
Clerico M., Rivorio C., Contessa G. et al. The therapy of multiple sclerosis with
immune-modulating or immunosupressive drug. A critical evaluation based upon
evidence based parameters and published systematic reviews // Clin. Neurol.
Neurosirg.
–
2008.
–
Vol. 110, № 9. –
P. 878-886.
Clifford D.B., De Luca A., Simpson D.M. et al. Natalizumab-associated progressive
multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28
cases // Lancet Neurol.
–
2010.
–
Vol. 9, № 4. –
P. 438-446.
Chuang Y.C., Lee C.T., Chen J.B., Chee E.C. Experience in the treatment of
myasthenia gravis with double filtration plasmapheresis // Chang Gung Med. J.
–
2000.
–
Vol. 23, № 2. –
P. 80-86.
Cortese I., Chaudhry V., So Y.T et al. Evidence-based guideline update:
Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology
Assessment Subcommitee of the American Academy of Neurology // Neurology.
–
2011.
–
Vol. 76, №3. –
P. 294-298.
Dada M.A., Kaplan A.A. Plasmapheres treatment in Guillain-Barr
é
syndrome:
potential benefit over IVIg in patients with axonal involvement // Ther. Apher. Dial.
–
2004.
–
Vol. 8, № 5. –
P.409-412.
Dalakas
M.C.
Basic
aspects
of
neuroimmunology
as
they relate to
immunotherapeutic targets: present and future prospects // Ann. Neurol. - 1995. - Vol.
37, Suppl. 1. - P. S2-S13.
Dau P.C., Denis E.H. Plasmapheresis and immunosupressive drug therapy in the
Eaton-Lambert syndrome // Ann. Neurol. - 1982. -
Vol. 11, № 6.
- P. 570-575.
De Lau L.M., Siepman D.A., Remmers M.J. et al. Acute disseminating
encephalomyelitis following legionnairs disease // Arch. Neurol.
–
2010.
–
Vol. 67, № 5.
–
P.623-626.
Dhand U.K. Clinical approach to the weak patient in the intensive care unit // Respir.
Care.
–
2-1-.
–
Vol. 51, № 9.
–
P. 1024-1040.
Dick P.J., Low P.A., Windebank A.J. et al. Plasma exchange in polyneuropathy
associated worth monoclonal gammapathy of undetermined significance // N. Eng. J.
Med. - 1991. -
Vol. 325, № 21.
- P. 1482-1486.
Dick P.J., Litchy W.J., Kratz K.M. et al. A plasma exchange versus immune globulin
infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy // Ann.
Neurol. - 1994. -
Vol. 36, № 6.
- P. 838-845.
Dropcho E.J. Autoimmune central nervous system paraneoplastic disorders:
mechanisms, diagnosis, and therapeutic options // Ann. Neurol. - 1995. - Vol. 37, Suppl.
1. - P. S102-S113.
19
El-Bawab H., Hajjar W., Rafay M. et al. Plasmapheresis before thymectomy in
myasthenia gravis: routine versus selective protocols // Eur. J. Cardiovasc. Surg.
–
2009.
–
Vol. 35,
№ 3. –
P. 392-397.
El-Bayoumi M.A., El-Rafaey A.M., Abdelkader A.M. et al. Comparison of
intravenous immunoglobulin and plasma exchange in treatment of mechanically
ventilated children with Guillain-Barr
é
syndrome: a randomized study // Crit. Care.
–
2011.
–
Vol. 15, № 4. –
P. R164.
Fernand
é
z A.A., Martin A.P., Martinez M.I. et al. Cronic fatigue syndrome :
aetiology, diagnosis and treatment // BMC Psychiatry.
–
2009.
–
Vol. 9, Suppl 1.
–
P.
S1.
Fleury M.C., Tranchant C. Myasthenia gravis // Rev. Prat.
–
2008.
–
Vol. 58, № 20.
–
P. 2217-2224.
Fogan L. Progressive encephalomyelitis with rigidity responsive to plasmapheresis
and immunosupression // Ann. Neurol. - 1996. -
Vol. 40, № 4,
-- P. 451-453.
Fukazawa T., Kikuchi S., Sasaki H. et al. Antinuclear antibodies and the optic-spinal
form of multiple sclerosis // J. Neurol. - 1997. -
Vol. 244, № 8.
- P. 483-488.
Gaidos P., Chevret S., Clair B. et al. Clinical trial of plasma exchange and high-dose
intravenous immunoglobulin in myasthenia Gravis // Ann. Neurol. - 1997. -
Vol. 41, № 6.
- P. 789-796.
Gambetti P., Parch P. Insomnia in prion diseases: sporadic and familial // New Engl.
J. Med. - 1999. -
Vol. 340, № 21.
- P. 1675-1677.
Geschwind M.D., Tan KL.M., Lennon V.A. et al. Voltage-gated potassium channel
autoimmunity mimicking Creutzfeldt-Jalob disease // Arch. Neurol.
–
2008.
–
Vol. 65, №
10.
–
P. 1341-1346.
Gold R., Schneider-Gold C. Current and future standarts in treatment of myasthenia
gravis // Neurotherapeutics.
–
2008.
–
Vol. 5, № 4. –
P. 535-541.
Gold R., Hohlfeld R., Toyka K.V. Progress in the treatment of myasthenia gravis //
Ther. Adv. Neurol. Disord.
–
2008.
–
Vol. 1, № 2. –
P. 36-51.
Gorson K.C. An update on the management of chronic inflammatory demyelinating
polyneuropathy // Ther. Adv. Neurol. Disord.
–
2012.
–
Vol. 5, № 6. –
P. 359-373.
Graf W.D., Katz J.S., Eder D.N. et al. Outcome in severe pediatric Guillain-
Barré
syndrome after immunotherapy or supportive care // Neurology. - 1994. -
Vol, № 7.
- P.
1494-1497.
Graus F., Vega F., Delatre J.Y. et al. Plasmapheresis and antineoplastic treatment
CNS paraneoplastic syndrome with antineuronal autoantibodies // Neurology. - 1992. -
Vol. 42, № 3.
- P. 536-540.
Greenberg S.M., Hyman B.T. Cerebral amyloid angiopathy and apolipoptotein E:
bad news to the good allele? // Ann. Neurol. - 1997. -
Vol. 41, № 6.
- P. 701-702.
Gwathmey K., Balogun R.A., Burns T. Neurologic indications for therapeutic plasma
exchange: an apdate // J. Clin. Apher.
–
2011.
–
Vol. 26, № 5. –
P. 261-268.